Search results
Showing 106 to 120 of 128 results for epilepsy
pharmaco-resistance. Source guidance details Comes from guidance Epilepsies: diagnosis and management Number CG137 Date issued
Past technology appraisal appeals and decisions
care. Source guidance details Comes from guidance Epilepsies: diagnosis and management Number CG137 Date issued
Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)
This guideline covers recognising, diagnosing and managing vitamin B12 deficiency in people aged 16 and over, including deficiency caused by autoimmune gastritis. It also covers monitoring for gastric cancer in people with autoimmune gastritis.
This quality standard covers care and support and services for children, young people and adults with a learning disability (or a learning disability and autism) and behaviour that challenges, and their families and carers. It describes high quality care in priority areas for improvement.
View quality statements for QS101Show all sections
Sections for QS101
- Quality statements
- Quality statement 1: Lead commissioner
- Quality statement 2: Annual health check
- Quality statement 3: Initial assessment of behaviour that challenges
- Quality statement 4: Named lead practitioner
- Quality statement 5: Involving families and carers
- Quality statement 6: Parent-training programmes
- Quality statement 7: Personalised daily activities
This guideline has been updated and replaced by NICE guideline CG137.
This guidance has been updated and replaced by NICE guideline NG217.
This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.
The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)
NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)
Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women and pregnant people to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.
View recommendations for NG235Show all sections
Sections for NG235
- Overview
- Recommendations
- Recommendations for research
- Rationale and impact
- Context
- Appendix A: Adverse outcomes for different places of birth
- Appendix B: Outcomes for different places of birth – by BMI at booking
- Appendix C: Outcomes for intravenous remifentanil patient-controlled analgesia (PCA) compared with intramuscular pethidine
NICE is committed to supporting the national agenda for achieving a sustainable health and care system.
Mental health is one of the key clinical areas of health inequalities identified in NHS England’s Core20PLUS5 framework for children and young people.
Epilepsy is one of the key clinical areas of health inequalities identified in NHS England’s Core20PLUS5 framework for children and young people.